We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release third-quarter 2021 results on Nov 4, before the opening bell.
The company has an impressive track record. In the last reported quarter, it beat earnings expectations by 31.97%. It surpassed earnings estimates by 18.66%, on average, in the last four quarters.
Regeneron Pharmaceuticals, Inc. Price and Consensus
Our proven model predicts an earnings beat for Regeneron this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. That is the case here.
Earnings ESP: Earnings ESP of Regeneron is +8.78%, as the Zacks Consensus Estimate is pegged at $9.81 and the Most Accurate Estimate stands at $10.67.
Zacks Rank: It currently carries a Zacks Rank #1.
Factors to Note
A major chunk of Regeneron’s revenues comes from the sales of its key drug, Eylea, which is approved for various ophthalmology indications (neovascular age-related macular degeneration, diabetic macular edema, and macular edema, among others). Eylea was developed in collaboration with Bayer AG. Regeneron records net product sales of Eylea in the United States while Bayer records net product sales of the drug outside the country. Regeneron also records its share of profits/losses in connection with sales of Eylea outside the United States.
Eylea sales in the previous quarter came in at $1.42 billion in the United States. Sales in the quarter under review have most likely witnessed sequential growth with the normalizing of demand. The Zacks Consensus Estimate for Eylea sales in the United States is pegged at $1.46 billion.
Regeneron has a collaboration agreement with Sanofi (SNY - Free Report) for some of its other drugs like Dupixent and Kevzara. Apart from Eylea, investors will be focusing on asthma drug Dupixent’s (sales are recorded by Sanofi) performance and label expansion. The drug has been the company’s primary growth driver in the last few quarters. Regeneron records its share of profits/losses in connection with global sales of Dupixent and Kevzara.
Dupixent maintained its stellar performance on continuous label expansion and the trend is expected to have continued in the to-be-reported quarter. Total sales in the last quarter came in at $1.5 billion. Label expansion of the drug in the last few months is likely to have boosted sales further and resulted in incremental results. The Zacks Consensus Estimate for Dupixent sales is pegged at $1.56 billion.
Investors will focus on the performance of PCSK9 inhibitor, Praluent, and Libtayo. Regeneron records net product sales of Libtayo in the United States and Sanofi records net product sales of the drug outside the United States. The parties equally share profits/losses in connection with global sales of Libtayo.
Sales of Libtayo came in at $116.9 million in the previous quarter. Sales are likely to have recorded sequential growth in the to-be-reported quarter on recent label expansions.
Effective Apr 1, 2020, Regeneron records net product sales of Praluent in the United States. Sanofi records net product sales of the drug outside the United States and pays Regeneron a royalty on such sales. Total sales in the previous quarter came in at $99.4 million. Praluent sales are likely to have recorded sequential growth. The Zacks Consensus Estimate for Praluent sales is pegged at $103 million.
Apart from these, the company recorded sales of $2.6 billion (in the United States) from REGEN-COV in the previous quarter. REGEN-COV is a cocktail of two monoclonal antibodies (casirivimab and imdevimab, also known as REGN10933 and REGN10987, respectively). REGEN-COV received an Emergency Use Authorization from the FDA in November 2020 for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. In July, the FDA expanded the authorization for the cocktail for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are at high risk of exposure to an infected individual in an institutional setting. Sales are expected to have recorded sequential growth in the to-be-reported quarter as the pandemic continues to wreak havoc and on expanded authorizations.
Key Recent Developments
In August, the U.K’s Medicines and Healthcare products Regulatory Agency granted Conditional Marketing Authorization (CMA) for the casirivimab and imdevimab antibody cocktail (Ronapreve in the U.K. and other countries), to prevent and treat acute COVID-19 infection. In September, Regeneron announced that the U.S. Department of Health and Human Services and the Department of Defense will purchase 1.4 million additional doses of REGEN-COV.
Share Price Performance
Regeneron’s shares have gained 32.5% in the year so far against the industry’s decline of 10.1%.
Image Source: Zacks Investment Research
Other Stocks to Consider
Here are a couple of other drug/biotech stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.
Image: Bigstock
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is scheduled to release third-quarter 2021 results on Nov 4, before the opening bell.
The company has an impressive track record. In the last reported quarter, it beat earnings expectations by 31.97%. It surpassed earnings estimates by 18.66%, on average, in the last four quarters.
Regeneron Pharmaceuticals, Inc. Price and Consensus
Regeneron Pharmaceuticals, Inc. price-consensus-chart | Regeneron Pharmaceuticals, Inc. Quote
What Our Model Predicts
Our proven model predicts an earnings beat for Regeneron this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. That is the case here.
Earnings ESP: Earnings ESP of Regeneron is +8.78%, as the Zacks Consensus Estimate is pegged at $9.81 and the Most Accurate Estimate stands at $10.67.
Zacks Rank: It currently carries a Zacks Rank #1.
Factors to Note
A major chunk of Regeneron’s revenues comes from the sales of its key drug, Eylea, which is approved for various ophthalmology indications (neovascular age-related macular degeneration, diabetic macular edema, and macular edema, among others). Eylea was developed in collaboration with Bayer AG. Regeneron records net product sales of Eylea in the United States while Bayer records net product sales of the drug outside the country. Regeneron also records its share of profits/losses in connection with sales of Eylea outside the United States.
Eylea sales in the previous quarter came in at $1.42 billion in the United States. Sales in the quarter under review have most likely witnessed sequential growth with the normalizing of demand. The Zacks Consensus Estimate for Eylea sales in the United States is pegged at $1.46 billion.
Regeneron has a collaboration agreement with Sanofi (SNY - Free Report) for some of its other drugs like Dupixent and Kevzara. Apart from Eylea, investors will be focusing on asthma drug Dupixent’s (sales are recorded by Sanofi) performance and label expansion. The drug has been the company’s primary growth driver in the last few quarters. Regeneron records its share of profits/losses in connection with global sales of Dupixent and Kevzara.
Dupixent maintained its stellar performance on continuous label expansion and the trend is expected to have continued in the to-be-reported quarter. Total sales in the last quarter came in at $1.5 billion. Label expansion of the drug in the last few months is likely to have boosted sales further and resulted in incremental results. The Zacks Consensus Estimate for Dupixent sales is pegged at $1.56 billion.
Investors will focus on the performance of PCSK9 inhibitor, Praluent, and Libtayo. Regeneron records net product sales of Libtayo in the United States and Sanofi records net product sales of the drug outside the United States. The parties equally share profits/losses in connection with global sales of Libtayo.
Sales of Libtayo came in at $116.9 million in the previous quarter. Sales are likely to have recorded sequential growth in the to-be-reported quarter on recent label expansions.
Effective Apr 1, 2020, Regeneron records net product sales of Praluent in the United States. Sanofi records net product sales of the drug outside the United States and pays Regeneron a royalty on such sales. Total sales in the previous quarter came in at $99.4 million. Praluent sales are likely to have recorded sequential growth. The Zacks Consensus Estimate for Praluent sales is pegged at $103 million.
Apart from these, the company recorded sales of $2.6 billion (in the United States) from REGEN-COV in the previous quarter. REGEN-COV is a cocktail of two monoclonal antibodies (casirivimab and imdevimab, also known as REGN10933 and REGN10987, respectively). REGEN-COV received an Emergency Use Authorization from the FDA in November 2020 for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. In July, the FDA expanded the authorization for the cocktail for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are at high risk of exposure to an infected individual in an institutional setting. Sales are expected to have recorded sequential growth in the to-be-reported quarter as the pandemic continues to wreak havoc and on expanded authorizations.
Key Recent Developments
In August, the U.K’s Medicines and Healthcare products Regulatory Agency granted Conditional Marketing Authorization (CMA) for the casirivimab and imdevimab antibody cocktail (Ronapreve in the U.K. and other countries), to prevent and treat acute COVID-19 infection. In September, Regeneron announced that the U.S. Department of Health and Human Services and the Department of Defense will purchase 1.4 million additional doses of REGEN-COV.
Share Price Performance
Regeneron’s shares have gained 32.5% in the year so far against the industry’s decline of 10.1%.
Other Stocks to Consider
Here are a couple of other drug/biotech stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.
Exelixis (EXEL - Free Report) has an Earnings ESP of +20.00% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals (VRTX - Free Report) has an Earnings ESP of +10.62% and a Zacks Rank #2.